CAS 2161380-87-4

Chemistry, 1 End Use API, 3 Related Intermediates

Manufacturers/Suppliers

1 Suppliers

1 Suppliers

Also known as: 2161380-87-4, 5-bromo-4-(4-chlorothiophen-2-yl)thiazol-2-amine (avatrombopag impurity), Schembl19966961, Amy40538, Cs-0377234, F83912

Molecular Formula

C₇H₄BrClN₂S₂

Molecular Weight

295.6 g/mol

InChI Key

NDDIDWDEBBDFIE-UHFFFAOYSA-N

1 2D Structure

CAS 2161380-87-4

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5-bromo-4-(4-chlorothiophen-2-yl)-1,3-thiazol-2-amine

2.1.2 InChI

InChI=1S/C7H4BrClN2S2/c8-6-5(11-7(10)13-6)4-1-3(9)2-12-4/h1-2H,(H2,10,11)

2.1.3 InChI Key

NDDIDWDEBBDFIE-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1=C(SC=C1Cl)C2=C(SC(=N2)N)Br

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. 2161380-87-4

2. 5-bromo-4-(4-chlorothiophen-2-yl)thiazol-2-amine (avatrombopag Impurity)

3. Schembl19966961

4. Amy40538

5. Cs-0377234

6. F83912

2.3 Create Date

2018-06-23

3 Chemical and Physical Properties

Molecular Formula	C₇H₄BrClN₂S₂
Molecular Weight	295.6 g/mol
XLogP3	3.6
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	1
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	95.4
Heavy Atom Count	13
Formal Charge	0
Complexity	197
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

List of Suppliers

Full Screen View

Reset Filter

Ask Us

Tianjin Hankang Pharmaceutical Biot...

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

China

Virtual Booth

Digital Content

5-Chloro-6-[4-(ethoxycarbonyl)piperidino]nicotinic acid

PDF Supplier PDF

URL Supplier Web Content

CAS Number

931395-73-2

End Use API

Avatrombopag Maleate

About the Company

Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enter...

Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enterprise in China. Focused on generic drugs while venturing into innovative ones, the group is dedicated to offering comprehensive solutions to the industry. Presently, Hankang has crafted over 200 varieties for 600+ domestic and international companies, serving 10+ innovative drugs. It has successfully developed more than 10 initial generic drugs, with over 20 varieties endorsed by the top three domestic companies and 30 exceeding a 100 million output value.

ASK
US